Table 7. ADMET Properties of 5a–j.

entry	in vivo BBB penetration (C.brain/C.blood)a	in vitro Caco-2 cell permeability(nm/s)b	human intestinal absorption(HIA, %)c	in vitro MDCK cell permeability(nm/s)d	in vitro plasma protein binding (%)e	toxicityf
5a	1.2749	21.7129	89.5313	191.0100	95.7056	negative
5b	2.5729	21.7217	97.2754	79.4515	99.2126	negative
5c	0.4368	21.7072	89.8057	122.3450	90.6733	negative
5d	0.4900	18.8444	94.9217	27.9760	91.1146	negative
5e	0.6212	21.7231	94.1342	74.8857	96.2773	negative
5f	1.2911	21.4068	96.4950	38.0802	98.2989	negative
5g	0.7318	21.6890	88.5328	186.4370	93.6175	negative
5h	0.4699	21.7074	92.7086	87.8067	93.2263	negative
5i	0.4518	21.6737	86.9710	122.9902	94.1828	negative
5j	0.4560	16.1225	94.4193	29.6239	94.1007	negative

^aBBB penetration = [brain]/[blood].

^bCaco-2 cells derived from human colon adenocarcinoma, possessing multiple drug transport pathways through intestinal epithelium.

^cHIA (human intestinal absorption), the sum of absorption and bioavailability evaluated from ratio of excretion in urine, bile, and feces.

^dMDCK cell system is used as a tool for rapid permeability screening.

^e% of drug that binds to plasma protein.

^fIn vitro Ames test by metabolic and nonmetabolic activated TA100 and TA1535 strains collected from rat liver homogenate.